Cinclus Pharma
Stabilization notice
Carnegie Investment Bank AB (publ) (“Carnegie”), acting as stabilization manager, notifies that stabilization measures have been undertaken in the ordinary shares of Cinclus Pharma Holding AB (publ) (“Cinclus Pharma” or the “Company”) on Nasdaq Stockholm.
As announced on 20 June 2024 in connection with the offering of ordinary shares in the Company and the admission to trading of the Company’s ordinary shares on Nasdaq Stockholm, Carnegie is acting as stabilization manager and may effect transactions aimed at supporting the market price of the ordinary shares at levels above those which might otherwise prevail in the open market. Such stabilization transactions may be effected on Nasdaq Stockholm, in the over-the-counter market or otherwise, at any time during the period starting on the date of commencement of trading in the ordinary shares on Nasdaq Stockholm and ending no later than 30 calendar days thereafter.
Stabilization may terminate at any time without prior notice. In no event will transactions be effected at levels above the offering price of SEK 42. No later than by the end of the seventh trading day after stabilization transactions have been undertaken, Carnegie shall disclose that stabilization transactions have been undertaken. Within one week of the end of the stabilization period, Carnegie will make public the date at which stabilization started, the date at which stabilization last occurred and the price range within which stabilization was carried out, for each of the dates during which stabilization transactions were carried out.
The Company has granted an over-allotment option to Carnegie Investment Bank AB (publ), Bryan, Garnier & Co. Limited, Bryan Garnier Securities SAS and ABG Sundal Collier AB (the “Joint Bookrunners”), entailing that the Joint Bookrunners, no later than 30 days from the first day of trading in the Company’s ordinary shares on Nasdaq Stockholm, have the right to request that a maximum of 1,702,381 additional ordinary shares are issued by the Company, corresponding to a maximum of 10 percent of the total number of ordinary shares in the offering at a price corresponding to the offering price of SEK 42, in order to cover possible over-allotment within the framework of the offering.
Carnegie has, in its capacity as stabilization manager, notified that stabilization measures have been undertaken in accordance with article 5(4) in the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052, on Nasdaq Stockholm as specified below.
The contact person at Carnegie is Anna Boqvist (phone: +46 (8) 5886 88 54).
Stabilization information | |
Issuer: | Cinclus Pharma Holding AB (publ) |
Securities: | Ordinary shares, ISIN: SE0020388577 |
Offering size: | 18,726,191 ordinary shares (of which 1,702,381 refers to the over-allotment option) |
Offering price: | SEK 42 |
Ticker: | CINPHA |
Stabilization manager: | Carnegie Investment Bank AB (publ) |
Stabilization transactions | ||||||
Date | Number of shares | Highest price | Lowest price | Volume weighted average price | Currency | Trading venue |
2024-06-20 | 851,203 | 40.0000 | 32.6050 | 37.4392 | SEK | Nasdaq Stockholm |
2024-06-24 | 81,173 | 33.1000 | 32.1150 | 32.7209 | SEK | Nasdaq Stockholm |
2024-06-25 | 67,005 | 33.1000 | 32.1000 | 32.6634 | SEK | Nasdaq Stockholm |
2024-06-26 | 20,000 | 32.9000 | 30.5000 | 31.2225 | SEK | Nasdaq Stockholm |
2024-06-27 | 45,000 | 31.0000 | 30.4000 | 30.6886 | SEK | Nasdaq Stockholm |
2024-06-28 | 40,000 | 31.7000 | 31.0000 | 31.1908 | SEK | Nasdaq Stockholm |
2024-07-01 | 40,000 | 31.8000 | 30.7000 | 31.4345 | SEK | Nasdaq Stockholm |
Datum | 2024-07-01, kl 18:30 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)